ETC
NVCR icon

Exchange Traded Concepts’s NovoCure NVCR Stock Holding History

Exchange Traded Concepts’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$818K Sell
54,001
-13,168
-20% -$199K ﹤0.01% 1000
2026
Q1 		$732K Sell
67,169
-6,551
-9% -$81.8K 0.01% 937
2025
Q4 		$953K Buy
73,720
+9,621
+15% +$124K 0.01% 827
2025
Q3 		$828K Buy
64,099
+22,383
+54% +$299K 0.01% 853
2025
Q2 		$743K Buy
41,716
+3,904
+10% +$68K 0.01% 809
2025
Q1 		$674K Buy
37,812
+9,001
+31% +$204K 0.01% 732
2024
Q4 		$859K Sell
28,811
-19,616
-41% -$415K 0.02% 623
2024
Q3 		$757K Buy
48,427
+8,272
+21% +$150K 0.02% 657
2024
Q2 		$688K Sell
40,155
-18,775
-32% -$330K 0.02% 577
2024
Q1 		$921K Sell
58,930
-14,829
-20% -$218K 0.02% 452
2023
Q4 		$1.1M Buy
73,759
+22,627
+44% +$303K 0.03% 385
2023
Q3 		$826K Buy
51,132
+34,289
+204% +$989K 0.02% 424
2023
Q2 		$699K Sell
16,843
-983
-6% -$61K 0.02% 477
2023
Q1 		$1.07M Sell
17,826
-299
-2% -$23.9K 0.03% 318
2022
Q4 		$1.33M Buy
18,125
+368
+2% +$27.7K 0.04% 259
2022
Q3 		$1.35M Sell
17,757
-4,089
-19% -$319K 0.04% 205
2022
Q2 		$1.52M Sell
21,846
-10,189
-32% -$768K 0.04% 210
2022
Q1 		$2.65M Sell
32,035
-2,826
-8% -$208K 0.05% 183
2021
Q4 		$2.62M Buy
34,861
+20,985
+151% +$2.11M 0.05% 218
2021
Q3 		$1.61M Buy
13,876
+3,215
+30% +$486K 0.04% 249
2021
Q2 		$2.37M Sell
10,661
-2,505
-19% -$487K 0.07% 210
2021
Q1 		$1.74M Buy
13,166
+5,837
+80% +$923K 0.07% 211
2020
Q4 		$1.27M Sell
7,329
-1,997
-21% -$273K 0.06% 201
2020
Q3 		$1.04M Buy
9,326
+3,282
+54% +$262K 0.06% 164
2020
Q2 		$358K Buy
6,044
+4,370
+261% +$287K 0.06% 265
2020
Q1 		$113K Buy
1,674
+1,103
+193% +$87.2K 0.06% 249
2019
Q4 		$48K Buy
+571
New +$46.1K 0.01% 279

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Exchange Traded Concepts's NVCR Position: Q2 2026 in Review

Exchange Traded Concepts reduced its NovoCure (NVCR) stake by 20% in Q2 2026, selling an estimated $199K and leaving 54,001 shares worth $818K. The position accounts for ﹤0.01% of the portfolio, ranked #1000.

Exchange Traded Concepts first reported a position in NVCR in Q4 2019 and has held it in 27 quarters since. The position peaked at $2.65M in Q1 2022. 216 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

  • Exchange Traded Concepts held 54,001 shares of NovoCure worth $818K as of Q2 2026.
  • Exchange Traded Concepts sold 13,168 NovoCure shares in Q2 2026, an estimated $199K.
  • NovoCure made up ﹤0.01% of Exchange Traded Concepts's portfolio in Q2 2026, its #1000 holding.
  • Exchange Traded Concepts first reported a position in NovoCure in Q4 2019 and has held it in 27 quarters since.
  • Exchange Traded Concepts's NovoCure position peaked at $2.65M in Q1 2022.
  • 216 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on Exchange Traded Concepts's 13F filing for Q2 2026, filed 22 Jul 2026.